logo
Most Extreme Solar Storm Hit Earth 14,350 Years Ago

Most Extreme Solar Storm Hit Earth 14,350 Years Ago

Forbes25-05-2025
Illustration of a solar storm impacting the Earth.
Scientists have discovered a huge spike in radiocarbon levels 14,300 years ago by analyzing ancient tree-rings. The radiocarbon spike was caused by a massive solar storm, the biggest ever identified.
In the study, Postdoctoral Researcher Kseniia Golubenko and Professor Ilya Usoskin at the University of Oulu, Finland utilized their newly developed chemistry–climate model called SOCOL:14C-Ex, specifically designed to reconstruct solar particle storms under ancient glacial climate conditions. The model confirmed that the detected solar event was approximately 18 percent stronger than the notorious AD 775 event — until now the strongest solar storm ever recorded in tree-ring archives.
'Compared to the largest event of the modern satellite era — the 2005 particle storm — the ancient 12,350 BCE event was over 500 times more intense, according to our estimates', says Dr. Golubenko.
Other large solar storms have occurred around 7,176 BCE, 5,259 BCE, 663 BCE and 994 AD. A few other candidates are still under investigation.
The new chronology used wood samples recovered from the Drouzet River in the Southern French Alps. Here the river is cutting into ancient sediments, exposing fossil tree stumps dating back some 14,300 years.
Looking at the individual tree-ring allows researchers to reconstruct environmental and chemical changes for almost every year the tree lived. By stacking sections of different trees together, scientists can reconstruct a tree-ring record spanning many thousands of years.
Coronal mass ejections or flares are powerful outbursts of high-energy particles. When such a flare hits Earth, it can cause a solar storm. The particles coming from the sun collide with gases in Earth's atmosphere, forming new isotopes like the radioactive beryllium-10 and carbon-14 (or radiocarbon). Trees absorb these isotope, creating an isotopic record with their tree-rings.
'The ancient event in 12,350 BCE is the only known extreme solar particle event outside of the Holocene epoch, the past 12,000 years of stable warm climate', says Golubenko. This discovery is not only of great importance to better understand the how frequent extreme solar flares are, but also improves the use of radiocarbon to date archeological and biological samples. 'Our new model lifts the existing limitation to the Holocene and extends our ability to analyze radiocarbon data even for glacial climate conditions.'
'Miyake events (distinct spikes in past radiocarbon levels) allow us to pin down exact calendar years in floating archaeological chronologies', explains Usoskin. Radiocarbon signals from such events have already enabled researchers to precisely date Viking settlements in Newfoundland and Neolithic communities in Greece.
The largest, directly-observed, solar storm occurred in 1859 and is known as the Carrington Event. Polar lights were observed during daylight as far as the equator. At the time, long before mobile telecommunications and the widespread use of electronic devices, damage was fortunately quite limited.The solar storm recorded in the fossil trees was an estimated ten to hundred times more powerful.
Today the National Oceanic and Atmospheric Administration's Space Weather Prediction Center monitors solar activity and its impact on our infrastructure. Electronics with no electromagnetic shielding are still at a high risk of interference and jamming. A similar massive event happening today could be catastrophic for our technology-based society.
The study,"New SOCOL:14C-Ex model reveals that the Late-Glacial radiocarbon spike in 12350 BC was caused by the record-strong extreme solar storm," was published in the journal Earth and Planetary Science Letters.
Additional material and interviews provided by the University of Oslo.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

The massive blackout in Spain, Portugal, and France exposed a global power crisis. Now what?
The massive blackout in Spain, Portugal, and France exposed a global power crisis. Now what?

Fast Company

time6 hours ago

  • Fast Company

The massive blackout in Spain, Portugal, and France exposed a global power crisis. Now what?

On the morning of April 28, large parts of Spain, Portugal, and southern France went dark. A massive blackout left millions without power, halting trains mid-track, cutting mobile networks, and rattling the foundation of one of Europe's most advanced energy grids. In the days that followed, experts and media outlets scrambled to explain what had happened. Was it a cyberattack? Human error? A structural failure? More than two months later, official investigations are ongoing. Early statements by the Spanish government confirmed that although no single cause has emerged, it wasn't a cyberattack. While the exact cause remains under review, one thing the energy industry agrees on is clear: This can't keep happening. 'A relentless cycle of evolution' 'Power systems are not only extremely complex, they are also in a relentless cycle of evolution—with new parts coming in and old ones going out—all while remaining stable and dependable 24/7,' says Richard Schomberg, special envoy for smart electrification at the International Electrotechnical Commission (IEC).

Rituximab No Better Than Standard Therapy for EGPA Remission
Rituximab No Better Than Standard Therapy for EGPA Remission

Medscape

time6 hours ago

  • Medscape

Rituximab No Better Than Standard Therapy for EGPA Remission

TOPLINE: Rituximab did not show superiority over conventional therapy in inducing remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA). Both treatment groups had similar remission rates at 180 and 360 days, with no significant differences in relapse rates or adverse events. METHODOLOGY: A phase 3, multicenter, randomized, controlled superiority trial was conducted in France to compare rituximab with conventional therapy for EGPA remission induction. A total of 105 adult patients with active EGPA (mean age, 58.4 years; 52.4% women), defined by a Birmingham Vasculitis Activity Score (BVAS, version 3) ≥ 3, were enrolled between December 2016 and October 2019 and randomly assigned to receive either rituximab (n = 52) or conventional therapy on the basis of the five-factor score (n = 53). Patients in the rituximab group received 1 g of rituximab on days 1 and 15, along with glucocorticoids on a tapering schedule; those with a five-factor score ≥ 1 received placebo-cyclophosphamide and placebo-uromitexan. The conventional therapy group received glucocorticoids on a tapering schedule with or without cyclophosphamide on the basis of a five-factor score ≥ 1. The primary endpoint was the proportion of patients who achieved remission, defined as the absence of EGPA disease activity (indicated by a BVAS of 0 at a prednisone dose of ≤ 7.5 mg/d), at 180 days. Secondary endpoints included the duration of remission, glucocorticoid dose, and safety, with follow-up visits scheduled up to 360 days. TAKEAWAY: At 180 days, 63.5% of patients in the rituximab group and 60.4% in the conventional group achieved remission (relative risk, 1.05; P = .75). At 360 days, remission rates were similar between the groups: 59.6% in the rituximab group and 64.2% in the conventional group. The time to remission was a median of 2 weeks in both the groups. Among patients who achieved a BVAS of 0, the mean duration of remission was comparable — 48.5 weeks for rituximab and 49.1 weeks for conventional therapy. No significant differences were observed in relapse rates or serious adverse event rates between the rituximab and conventional therapy groups. Infections and cardiovascular events were the most common serious adverse events. IN PRACTICE: 'On the basis of the results of this trial, the role of rituximab in the therapeutic management of EGPA has been updated,' the authors of the study wrote. 'In most of the study population with nonsevere EGPA, the lack of a clinically meaningful effect of rituximab in addition to the conventional strategy of glucocorticoids alone may appropriately inform clinical decision-making,' they added. SOURCE: The study was led by Benjamin Terrier, MD, PhD, Université Paris Cité in Paris, France. It was published online on July 28, 2025, in Annals of Internal Medicine. LIMITATIONS: The study's design as a superiority trial may not adequately address the equivalence between rituximab and conventional therapy. The limited sample size, due to the rarity of EGPA, affected the precision of subgroup analyses. The focus on remission induction in the vasculitis phase may differ from other studies. DISCLOSURES: The study was funded by research grants from the French Ministry of Health and sponsored by Assistance Publique-Hôpitaux de Paris. Additional disclosures are noted in the original article online. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

France says European satellite venture talks are making progress
France says European satellite venture talks are making progress

Yahoo

time5 days ago

  • Yahoo

France says European satellite venture talks are making progress

PARIS (Reuters) -Efforts to set up a European space project alliance involving Italy's Leonardo, France's Thales and Airbus and aimed at challenging Elon Musk's Starlink are making progress, said France's industry minister on Thursday. "It's a project which we support. Talks are moving forward in a constructive manner," said France's Marc Ferracci during a meeting in Paris with his Italian counterpart Adolfo Urso. Urso said negotiations were aiming at giving the two countries an equal footing in the project, endorsed by French President Emmanuel Macron at the Paris Airshow in June. Under the so-called "Project Bromo", named after an Indonesian volcano, Leonardo, Thales and Airbus have been exploring plans to set up a new satellite manufacturing company to better compete with the U.S. and China, but so far progress has been modest. Leonardo's Chief Executive Roberto Cingolani said last month that the three companies would make another assessment on where the deal stands by the end of July. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store